手术前的腺苷酸与安慰剂,以防止手术并发症称为胰腺瘘
一项针对预防术后胰腺瘘的兰雷托肽的随机III期盲试验
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
研究概览
地位
详细说明
PRIMARY OBJECTIVE:
I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.
SECONDARY OBJECTIVES:
I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.
II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.
ADDITIONAL OBJECTIVES:
I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.
II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.
BANKING OBJECTIVE:
I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Dana Sparks
- 电话号码:210-614-8808
- 邮箱:dsparks@swog.org
研究联系人备份
- 姓名:Andrea Garcia
- 电话号码:210-614-8808
- 邮箱:agarcia@swog.org
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- 暂停
- University of Alabama at Birmingham Cancer Center
-
Daphne、Alabama、美国、36526
- 暂停
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope、Alabama、美国、36532
- 暂停
- Thomas Hospital
-
Mobile、Alabama、美国、36607
- 暂停
- Mobile Infirmary Medical Center
-
Saraland、Alabama、美国、36571
- 暂停
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Gilbert、Arizona、美国、85234
- 暂停
- Banner MD Anderson Cancer Center
-
-
California
-
Duarte、California、美国、91010
- 暂停
- City of Hope Comprehensive Cancer Center
-
La Jolla、California、美国、92093
- 招聘中
- UC San Diego Moores Cancer Center
-
接触:
- Site Public Contact
- 电话号码:858-822-5354
- 邮箱:cancercto@ucsd.edu
-
首席研究员:
- Andrew M. Lowy
-
Loma Linda、California、美国、92357
- 暂停
- Veterans Affairs Loma Linda Healthcare System
-
Los Angeles、California、美国、90033
- 暂停
- USC / Norris Comprehensive Cancer Center
-
San Diego、California、美国、92103
- 暂停
- UC San Diego Medical Center - Hillcrest
-
-
Delaware
-
Newark、Delaware、美国、19718
- 暂停
- Christiana Care Health System-Christiana Hospital
-
Newark、Delaware、美国、19713
- 暂停
- Helen F Graham Cancer Center
-
Newark、Delaware、美国、19713
- 暂停
- Medical Oncology Hematology Consultants PA
-
Wilmington、Delaware、美国、19801
- 暂停
- Christiana Care Health System-Wilmington Hospital
-
-
Florida
-
Ruskin、Florida、美国、33570
- 暂停
- Moffitt Cancer Center at SouthShore
-
Tampa、Florida、美国、33612
- 招聘中
- Moffitt Cancer Center - McKinley Campus
-
接触:
- Site Public Contact
- 电话号码:800-679-0775
- 邮箱:ClinicalTrials@moffitt.org
-
首席研究员:
- Andrew J. Sinnamon
-
Tampa、Florida、美国、33607
- 暂停
- Moffitt Cancer Center-International Plaza
-
Tampa、Florida、美国、33612
- 暂停
- Moffitt Cancer Center
-
Wesley Chapel、Florida、美国、33544
- 暂停
- Moffitt Cancer Center at Wesley Chapel
-
-
Georgia
-
Atlanta、Georgia、美国、30342
- 暂停
- Emory Saint Joseph's Hospital
-
Atlanta、Georgia、美国、30308
- 暂停
- Emory University Hospital Midtown
-
Atlanta、Georgia、美国、30322
- 暂停
- Emory University Hospital/Winship Cancer Institute
-
Atlanta、Georgia、美国、30303
- 暂停
- Grady Health System
-
Johns Creek、Georgia、美国、30097
- 暂停
- Emory Johns Creek Hospital
-
-
Illinois
-
Chicago、Illinois、美国、60611
- 招聘中
- Northwestern University
-
接触:
- Site Public Contact
- 电话号码:312-695-1301
- 邮箱:cancer@northwestern.edu
-
首席研究员:
- Akhil Chawla
-
Chicago、Illinois、美国、60612
- 招聘中
- University of Illinois
-
首席研究员:
- Aslam Ejaz
-
接触:
- Site Public Contact
- 电话号码:312-355-3046
-
Geneva、Illinois、美国、60134
- 暂停
- Northwestern Medicine Cancer Center Delnor
-
Oak Brook、Illinois、美国、60523
- 暂停
- Northwestern Medicine Oak Brook
-
Orland Park、Illinois、美国、60462
- 暂停
- Northwestern Medicine Orland Park
-
Warrenville、Illinois、美国、60555
- 暂停
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- 暂停
- Indiana University/Melvin and Bren Simon Cancer Center
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- 招聘中
- University of Kentucky/Markey Cancer Center
-
首席研究员:
- Michael J. Cavnar
-
接触:
- Site Public Contact
- 电话号码:859-257-3379
-
-
Louisiana
-
New Orleans、Louisiana、美国、70112
- 暂停
- University Medical Center New Orleans
-
-
Maryland
-
Elkton、Maryland、美国、21921
- 暂停
- Christiana Care - Union Hospital
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 暂停
- University of Michigan Rogel Cancer Center
-
Battle Creek、Michigan、美国、49017
- 暂停
- Bronson Battle Creek
-
Grand Rapids、Michigan、美国、49503
- 暂停
- Trinity Health Grand Rapids Hospital
-
Grand Rapids、Michigan、美国、49503
- 暂停
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Grand Rapids、Michigan、美国、49503
- 暂停
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Muskegon、Michigan、美国、49444
- 暂停
- Trinity Health Muskegon Hospital
-
Niles、Michigan、美国、49120
- 暂停
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores、Michigan、美国、49444
- 暂停
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City、Michigan、美国、49677
- 暂停
- Corewell Health Reed City Hospital
-
Saint Joseph、Michigan、美国、49085
- 暂停
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph、Michigan、美国、49085
- 暂停
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Wyoming、Michigan、美国、49519
- 暂停
- University of Michigan Health - West
-
-
Minnesota
-
Aitkin、Minnesota、美国、56431
- 暂停
- Riverwood Healthcare Center
-
Baxter、Minnesota、美国、56425
- 暂停
- Essentia Health - Baxter Clinic
-
Brainerd、Minnesota、美国、56401
- 暂停
- Essentia Health Saint Joseph's Medical Center
-
Crosslake、Minnesota、美国、56442
- 暂停
- Essentia Health - Saint Joseph's Crosslake Clinic
-
Deer River、Minnesota、美国、56636
- 暂停
- Essentia Health - Deer River Clinic
-
Detroit Lakes、Minnesota、美国、56501
- 暂停
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth、Minnesota、美国、55805
- 暂停
- Essentia Health Saint Mary's Medical Center
-
Duluth、Minnesota、美国、55805
- 暂停
- Miller-Dwan Hospital
-
Duluth、Minnesota、美国、55805
- 暂停
- Essentia Health Cancer Center
-
Ely、Minnesota、美国、55731
- 暂停
- Essentia Health - Ely Clinic
-
Fosston、Minnesota、美国、56542
- 暂停
- Essentia Health - Fosston
-
Hibbing、Minnesota、美国、55746
- 暂停
- Essentia Health Hibbing Clinic
-
International Falls、Minnesota、美国、56649
- 暂停
- Essentia Health - International Falls Clinic
-
Moose Lake、Minnesota、美国、55767
- 暂停
- Essentia Health - Moose Lake Clinic
-
Park Rapids、Minnesota、美国、56470
- 暂停
- Essentia Health - Park Rapids
-
Pequot Lakes、Minnesota、美国、56472
- 暂停
- Essentia Health - Saint Joseph's Pequot Lakes Clinic
-
Pine River、Minnesota、美国、56474
- 暂停
- Essentia Health - Saint Joseph's Pine River Clinic
-
Sandstone、Minnesota、美国、55072
- 暂停
- Essentia Health Sandstone
-
Staples、Minnesota、美国、56479
- 暂停
- Essentia Health - Saint Joseph's Staples Clinic
-
Virginia、Minnesota、美国、55792
- 暂停
- Essentia Health Virginia Clinic
-
-
Missouri
-
Farmington、Missouri、美国、63640
- 招聘中
- Parkland Health Center - Farmington
-
首席研究员:
- Bryan A. Faller
-
接触:
- Site Public Contact
- 电话号码:314-996-5569
-
Sainte Genevieve、Missouri、美国、63670
- 招聘中
- Sainte Genevieve County Memorial Hospital
-
首席研究员:
- Bryan A. Faller
-
接触:
- Site Public Contact
- 电话号码:314-996-5569
-
St Louis、Missouri、美国、63131
- 招聘中
- Missouri Baptist Medical Center
-
首席研究员:
- Bryan A. Faller
-
接触:
- Site Public Contact
- 电话号码:314-996-5569
-
Sullivan、Missouri、美国、63080
- 招聘中
- Missouri Baptist Sullivan Hospital
-
首席研究员:
- Bryan A. Faller
-
接触:
- Site Public Contact
- 电话号码:314-996-5569
-
Sunset Hills、Missouri、美国、63127
- 招聘中
- BJC Outpatient Center at Sunset Hills
-
首席研究员:
- Bryan A. Faller
-
接触:
- Site Public Contact
- 电话号码:314-996-5569
-
-
Nebraska
-
Omaha、Nebraska、美国、68198
- 暂停
- University of Nebraska Medical Center
-
-
Nevada
-
Reno、Nevada、美国、89502
- 暂停
- Renown Regional Medical Center
-
-
New Jersey
-
Livingston、New Jersey、美国、07039
- 暂停
- Saint Barnabas Medical Center
-
New Brunswick、New Jersey、美国、08903
- 暂停
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87106
- 暂停
- University of New Mexico Cancer Center
-
-
New York
-
Rochester、New York、美国、14642
- 暂停
- University of Rochester
-
Syracuse、New York、美国、13210
- 暂停
- State University of New York Upstate Medical University
-
-
North Carolina
-
Charlotte、North Carolina、美国、28203
- 暂停
- Carolinas Medical Center/Levine Cancer Institute
-
Concord、North Carolina、美国、28025
- 暂停
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Fargo、North Dakota、美国、58103
- 暂停
- Essentia Health Cancer Center-South University Clinic
-
Fargo、North Dakota、美国、58122
- 暂停
- Sanford Roger Maris Cancer Center
-
Fargo、North Dakota、美国、58122
- 暂停
- Sanford Broadway Medical Center
-
Jamestown、North Dakota、美国、58401
- 暂停
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- 暂停
- University of Cincinnati Cancer Center-UC Medical Center
-
Columbus、Ohio、美国、43210
- 暂停
- Ohio State University Comprehensive Cancer Center
-
West Chester、Ohio、美国、45069
- 暂停
- University of Cincinnati Cancer Center-West Chester
-
-
Pennsylvania
-
Allentown、Pennsylvania、美国、18104
- 招聘中
- Saint Luke's Cancer Center - Allentown
-
接触:
- Site Public Contact
- 电话号码:610-776-4714
-
首席研究员:
- Darius C. Desai
-
Bethlehem、Pennsylvania、美国、18015
- 招聘中
- Saint Luke's University Hospital-Bethlehem Campus
-
接触:
- Site Public Contact
- 电话号码:484-503-4151
-
首席研究员:
- Darius C. Desai
-
Chadds Ford、Pennsylvania、美国、19317
- 暂停
- Christiana Care Health System-Concord Health Center
-
Easton、Pennsylvania、美国、18045
- 招聘中
- Saint Luke's Hospital-Anderson Campus
-
接触:
- Site Public Contact
- 电话号码:888-823-5923
- 邮箱:ctsucontact@westat.com
-
首席研究员:
- Darius C. Desai
-
Quakertown、Pennsylvania、美国、18951
- 招聘中
- Saint Luke's Hospital - Upper Bucks Campus
-
接触:
- Site Public Contact
- 电话号码:610-776-4714
-
首席研究员:
- Darius C. Desai
-
Stroudsburg、Pennsylvania、美国、18360
- 招聘中
- Saint Luke's Hospital - Monroe Campus
-
接触:
- Site Public Contact
- 电话号码:888-823-5923
- 邮箱:ctsucontact@westat.com
-
首席研究员:
- Darius C. Desai
-
Wilkes-Barre、Pennsylvania、美国、18711
- 暂停
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57104
- 暂停
- Sanford Cancer Center Oncology Clinic
-
Sioux Falls、South Dakota、美国、57117-5134
- 暂停
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville、Tennessee、美国、37920
- 暂停
- University of Tennessee - Knoxville
-
Memphis、Tennessee、美国、38120
- 暂停
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Vermont
-
Burlington、Vermont、美国、05405
- 暂停
- University of Vermont and State Agricultural College
-
Burlington、Vermont、美国、05401
- 暂停
- University of Vermont Medical Center
-
-
Virginia
-
Richmond、Virginia、美国、23235
- 招聘中
- VCU Massey Cancer Center at Stony Point
-
接触:
- Site Public Contact
- 邮箱:ctoclinops@vcu.edu
-
首席研究员:
- Leopoldo J. Fernandez
-
Richmond、Virginia、美国、23298
- 招聘中
- VCU Massey Comprehensive Cancer Center
-
首席研究员:
- Leopoldo J. Fernandez
-
接触:
- Site Public Contact
- 电话号码:804-628-6430
- 邮箱:CTOclinops@vcu.edu
-
Roanoke、Virginia、美国、24033
- 暂停
- Carilion Roanoke Memorial Hospital
-
Winchester、Virginia、美国、22601
- 暂停
- Valley Health / Winchester Medical Center
-
-
Washington
-
Seattle、Washington、美国、98195
- 暂停
- University of Washington Medical Center - Montlake
-
Seattle、Washington、美国、98109
- 暂停
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Ashland、Wisconsin、美国、54806
- 暂停
- Northwest Wisconsin Cancer Center
-
Ashland、Wisconsin、美国、54806
- 暂停
- Duluth Clinic Ashland
-
Hayward、Wisconsin、美国、54843
- 暂停
- Essentia Health-Hayward Clinic
-
Hayward、Wisconsin、美国、54843
- 暂停
- Tamarack Health Hayward Medical Center
-
Marshfield、Wisconsin、美国、54449
- 招聘中
- Marshfield Medical Center-Marshfield
-
接触:
- Site Public Contact
- 电话号码:800-782-8581
- 邮箱:oncology.clinical.trials@marshfieldresearch.org
-
首席研究员:
- Jessica A. Wernberg
-
Mukwonago、Wisconsin、美国、53149
- 暂停
- ProHealth D N Greenwald Center
-
Oconomowoc、Wisconsin、美国、53066
- 暂停
- ProHealth Oconomowoc Memorial Hospital
-
Spooner、Wisconsin、美国、54801
- 暂停
- Essentia Health-Spooner Clinic
-
Superior、Wisconsin、美国、54880
- 暂停
- Essentia Health Saint Mary's Hospital - Superior
-
Waukesha、Wisconsin、美国、53188
- 暂停
- ProHealth Waukesha Memorial Hospital
-
Waukesha、Wisconsin、美国、53188
- 暂停
- UW Cancer Center at ProHealth Care
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential
-
Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date
-
Participants must not have a known history of a prior diagnosis of malabsorption syndrome
-
Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization
-
Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization
-
Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization
-
Participants must be ≥ 18 years old
-
Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization
-
Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization
-
Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:
- Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
- Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
- Bromocriptine: Dose adjustments may be considered to account for absorption changes
- Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
- CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy
- NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation
-
Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable
-
Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)
-
Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
-
Participants must be offered the opportunity to participate in specimen banking
-
Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study
-
NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
-
For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm I (lanreotide, distal pancreatectomy)
Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
其他名称:
Undergo distal pancreatectomy Given SC
其他名称:
|
|
安慰剂比较:Arm II (saline placebo, distal pancreatectomy)
Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
其他名称:
Undergo distal pancreatectomy Given SC
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of postoperative pancreatic fistula (POPF)
大体时间:Up to 60 days after distal pancreatectomy
|
POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of biochemical leak (BL)
大体时间:Up to 60 days after distal pancreatectomy
|
BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Number of post-operation hospital days
大体时间:From the time of surgery up to 60 days after distal pancreatectomy
|
Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor. |
From the time of surgery up to 60 days after distal pancreatectomy
|
|
Change in overall quality of life (QOL)
大体时间:At baseline and at 14 and 60 days after surgery
|
Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and at 14 and 60 days after surgery
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Changes in pancreatic specific QOL
大体时间:At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Change in health-related QOL
大体时间:At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Delayed gastric emptying (DGE)
大体时间:Up to 60 days after distal pancreatectomy
|
DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)
大体时间:Up to 60 days after distal pancreatectomy
|
PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Time to initiation of adjuvant chemotherapy
大体时间:From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test. |
From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
|
Incidence of nausea and vomiting
大体时间:Up to 60 days after distal pancreatectomy
|
Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test. |
Up to 60 days after distal pancreatectomy
|
合作者和调查者
调查人员
- 首席研究员:Jonathan G Sham、SWOG Cancer Research Network
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- S2408
- UG1CA189974 (美国 NIH 拨款/合同)
- NCI-2024-08361 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- SWOG-S2408 (其他标识符:DCP)
- S2408 (其他标识符:SWOG)
- S2408 (其他标识符:CTEP)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.